Patients with vertigo caused by psychological problems have increased in recent years. It has been reported that many outpatients with vertigo also suff er from depression. Selective serotonin reuptake inhibitors are widely used for the treatment of depression because of their effi cacy and relatively favorable side-eff ects profi le compared to those of tricyclic antidepressants. We used Paroxetine to treat patients with vertigo who were diagnosed with depression by self-rating questionnaires for depression (SRQ-D). Twenty-six patients experienced relief a er taking Paroxetine. Fi een of them were relieved of their vertigo symptoms, 8 were improved, one was not changed, and two were worse. SRQ-D scores were compared between the day of commencement and the day a er 4 weeks. Fi een patients were normalized. Side eff ects occurred in seven patients; nausea in fi ve and sleepiness in two. e average duration of taking the medicine was 24.4 weeks. Since Paroxetine showed benefi cial clinical eff ects for patients with vertigo, this medicine might be useful for vertiginous patients with depression.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.